Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorBiagetti Biagetti, Betina
dc.contributor.authorSimó Canonge, Rafael
dc.date.accessioned2022-05-02T12:01:48Z
dc.date.available2022-05-02T12:01:48Z
dc.date.issued2021-10
dc.identifier.citationBiagetti B, Simò R. Molecular Pathways in Prolactinomas: Translational and Therapeutic Implications. Int J Mol Sci. 2021 Oct;22(20):11247.
dc.identifier.issn1422-0067
dc.identifier.urihttp://hdl.handle.net/11351/7419
dc.descriptionDopamine; Lactotroph tumour; Prolactinoma
dc.description.abstractProlactinoma has the highest incidence rate among patients with functional pituitary tumours. Although mostly benign, there is a subgroup that can be aggressive. Some clinical, radiological and pathology features have been associated with a poor prognostic. Therefore, it can be considered as a group of heterogeneous tumours. The aim of this paper is to give an overview of the molecular pathways involved in the behaviour of prolactinoma in order to improve our approach and gain deeper insight into the better understanding of tumour development and its management. This is essential for identifying patients harbouring aggressive prolactinoma and to establish personalised therapeutics options.
dc.language.isoeng
dc.publisherMDPI
dc.relation.ispartofseriesInternational Journal of Molecular Sciences;22(20)
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectHipòfisi - Tumors - Tractament
dc.subjectDopamina - Agonistes - Ús terapèutic
dc.subject.meshPituitary Neoplasms
dc.subject.mesh/drug therapy
dc.subject.meshDopamine Agonists
dc.subject.mesh/therapeutic use
dc.titleMolecular Pathways in Prolactinomas: Translational and Therapeutic Implications
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.3390/ijms222011247
dc.subject.decsneoplasias hipofisarias
dc.subject.decs/farmacoterapia
dc.subject.decsagonistas dopaminérgicos
dc.subject.decs/uso terapéutico
dc.relation.publishversionhttps://doi.org/10.3390/ijms222011247
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliationUnitat de Recerca en Diabetis i Metabolisme, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain
dc.identifier.pmid34681905
dc.identifier.wos000715415400001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record